Non‐invasive foetal RHD genotyping via real‐time PCR of foetal DNA from Chinese RhD‐negative maternal plasma

  title={Non‐invasive foetal RHD genotyping via real‐time PCR of foetal DNA from Chinese RhD‐negative maternal plasma},
  author={X. D. Wang and B. L. Wang and Shuang Ye and Yan-Qiu Liao and L. F. Wang and Z. M. He},
  journal={European Journal of Clinical Investigation},
Background  A majority of studies predicting the foetal RhD blood group in free foetal DNA from RhD‐negative maternal plasma have been conducted in Caucasian populations, whereas limited data have been accumulated for Asian populations. In this study, we assessed the feasibility of prenatal genotyping of RHD in RhD‐negative Chinese pregnant women. 

Noninvasive fetal RHD genotyping using cell-free fetal DNA incorporating fetal RASSF1A marker in RhD-negative pregnant women in Korea

The HGVS nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics and is being implemented for genetic testing medical evidence review updates starting in 2017.

Noninvasive Prenatal Diagnosis of Fetal RHD Status Using Cell-free Fetal DNA in Maternal Plasma

The findings reveal that the strategy used in this study is reliable and it is possible to determine the fetal RHD status with high accuracy and can help targeted injection of RhIG and prevent unnecessary injection in RhDnegative mothers who carry an RhD negative fetus.

Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.

It is demonstrated thatfoetal RHD detection on maternal plasma using a commercial multiple-exon assay is a reliable and accurate tool to predict foetal RhD phenotype and can be a safe guide for the appropriate administration of targeted prenatal immunoprophylaxis.

Fetal RHD Genotyping from Circulating Cell-Free Fetal DNA in Plasma of Rh Negative Pregnant Women in Iran

The present study confirms the precision of fetal RHD and SRY genotyping in maternal plasma by real-time PCR technique and helps RhD negative pregnant women about the appropriate use of anti-D immunoglobulin and also on the management and prevention of HDFN.

Noninvasive fetal RHD genotyping from maternal plasma

Noninvasive fetal RHD typing can be performed in RhD-negative alloimmunization and nonimmunized pregnancies to decide on clinical management and to restrict the anti-D immunoglobulin prophylaxis, respectively.

RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in Ethiopia

Multi exon targeted non-invasive prenatal screening test for fetal RhD determination exhibited high accuracy and sensitivity and a confirmatory study with a bigger size of study subjects is warranted before enabling clinical implementation.

Fetal RHD Genotyping Using Real-Time Polymerase Chain Reaction Analysis of Cell-Free Fetal DNA in Pregnancy of RhD Negative Women in South of Iran

The results showed high accuracy of the qPCR method using cffDNA for fetal RHD genotyping and implicate on the efficiency of this technique to predict the competence of anti-D immunoglobulin administration.

[RHD genotyping from cell-free fetal DNA circulating in pregnant women peripheral blood and sensitivity assessment of innovated diagnostic approaches for introduction into the clinical practice].

Current established and routinely used procedure is based on the detection of exon 7 of the RHD gene and on the series of parallel amplification and contamination controls and both newly developed methods could be, after validation of the larger set of control samples, introduced into clinical practice.

Non-invasive fetal RHD genotyping

F fetal RhD genotyping enables antenatal prophylaxis to be targeted to only those women carrying a D-positive fetus to avoid unnecessary treatment, and is widely used to assess the risk of HDFN in anti-D immunized women.

The controversy about controls for fetal blood group genotyping by cell-free fetal DNA in maternal plasma

The analysis of recently published noninvasive fetal blood group genotyping studies showed that false-negative results were only encountered in studies lacking a control for the presence of fetal DNA, albeit at a low frequency of 0.1–0.2%.



Evaluation of prenatal RHD typing strategies on cell‐free fetal DNA from maternal plasma

Few assays are designed in such a way that the fetus can be typed in RHD mothers and that RHDψ fetuses are correctly typed, so precautions in developing prenatal genotyping strategies must be made.

Prenatal genotyping of RHD and SRY using maternal blood

The aim of the study was to perform fetal RHD genotyping in maternal plasma using a fluorescent polymerase chain reaction (PCR) technique and the effect of varying storage temperatures on the concentration of fetal DNA was investigated.

Noninvasive determination of fetal RHD status by examination of cell‐free DNA in maternal plasma

The focus was on accuracy of RHD typing and confirmation of fetal DNA in maternal plasma while RHD was not detected.

Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service

The detection of RHD sequences in maternal plasma has been used to predict fetal D status, based on the assumption that RHD is absent in D– genomes, and this data indicates that this assumption is likely to be correct.

Non-Invasive Fetal RHD Exon 7 and Exon 10 Genotyping Using Real-Time PCR Testing of Fetal DNA in Maternal Plasma

It is suggested that safe non-invasive prenatal foetal RHD genotyping using maternal plasma should involve the amplification of at least two RHD-specific products.

Non-invasive Fetal RHD and RHCE Genotyping Using Real-time PCR Testing of Maternal Plasma in RhD-negative Pregnancies

It is recommended to perform fetal RHD and RHCE genotyping together with fetal sex determination in alloimmunized D-negative pregnancies at risk of hemolytic disease of the newborn.

Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma.

Noninvasive fetal RhD genotyping can be performed rapidly and reliably with the use of maternal plasma beginning in the second trimester of pregnancy.

Prediction of fetal Rh D and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reaction.

  • T. LeglerR. Lynen M. Köhler
  • Medicine
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2002

Fetal rhd genotyping from maternal plasma in a population with a highly diverse ethnic background.

Conventional PCR is an accurate method for fetal RHD genotyping on maternal plasma, even in a population of mixed ethnic origin.